Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lenalidomide may stop the growth of cancer by blocking blood flow to the tumor.
Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some
block the ability of cancer cells to grow and spread. Others find cancer cells and help kill
them or carry cancer-killing substances to them. Giving lenalidomide together with rituximab
may be an effective treatment for B-cell non-Hodgkin lymphoma.
PURPOSE: This phase I/II trial is studying the side effects and best dose of lenalidomide
when given together with rituximab as maintenance therapy in treating patients with B-cell
non-Hodgkin lymphoma.